Connecting Innovation to Purpose

18 ● ● ● Clinical Pharmacology 21 Day PK Enfortumab vedotin (EV) 1.25 mg/kg Q1W x3 SYS6002 [CRB-701) 1.2 mg/kg Q3W SYS6002 (CRB-701) 2.7 mg/kg Q3W Comparison EV benchmark Matched ADC dose Matched MMAE dose Cmax 100% 79% 177% % ADC AUC 21d 100% 106% 183% Cmax 100% The half-lives of TAb, ADC, and MMAE were 4-6 days, 4-5 days and 5-10 days, respectively No obvious accumulation was observed on C3D1 33% 79% % Free MMAE AUC 21d 100% Time-to-peak concentration of MMAE was about 3-7 days When compared to EV exposures SYS6002 (CRB-701) consistently demonstrates lower free MMAE 29% After single IV infusion of SYS6002 (CRB-701), the exposure of TAb, ADC and MMAE generally increased in a dose proportional manner Clearance and volume of distribution were similar across doses 68%

View entire presentation